Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Turinabol, formally chlorodehydromethyltestosterone (CDMT) or 4-chlorodehydromethyltestosterone, is a synthetic anabolic-androgenic steroid (AAS) with a unique historical distinction: it is the only major AAS developed primarily for non-medical (athletic) purposes, rather than for therapeutic indications that later expanded to non-medical use. Patented in 1961 and first manufactured by the East German pharmaceutical company Jenapharm, turinabol was the central compound in State Plan Topic 14.25, the East German state-sponsored doping program that operated from approximately 1968 until the fall of the Berlin Wall in 1989.
Under this program, an estimated 10,000+ East German athletes, including swimmers, runners, weightlifters, and many other competitors, were administered turinabol, often under the deceptive label of "vitamins" and frequently without their informed consent. Many of these athletes, particularly women, suffered severe health consequences that emerged years later and continue to be documented in medical literature.
The compound has no injectable form in legitimate or common non-medical use.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Oral tablet (not esterified) | ~16 hours |
What it does
Main effects
- Moderate anabolic activity: favorable anabolic-to-androgenic ratio in animal assays (~54:6); produces gradual lean-mass gains rather than dramatic effects
- No aromatization to estrogen: C4 chlorine prevents conversion; no water retention, no estrogen-mediated gynecomastia, "dry" appearance
- Orally bioavailable via 17α-methyl modification (which is also the source of the hepatic risk)
- No water retention: basis of historical East German use (less visible physical changes than methandienone)
- Pronounced SHBG reduction in some user reports: potentially increases bioavailability of co-administered androgens
What to watch for
Common side effects
- Moderate hepatotoxicity via 17α-alkylation: generally less severe than oxymetholone or methylated testosterone, but still meaningful; cholestasis and (rarely) hepatic tumors documented
- HDL reduction and LDL elevation: moderate magnitude; less dramatic than stanozolol or oxymetholone but clinically meaningful
- Profound HPG axis suppression: strong suppression of LH, FSH, and endogenous testosterone
- Severe virilization in women: among the most extensively documented adverse-effect datasets in AAS history, from the East German doping program; voice deepening, clitoral enlargement, hirsutism, infertility, often irreversible
- Severe consequences with pediatric administration: premature epiphyseal closure, disrupted sexual development, transgenerational effects documented in children of affected East German athletes
- Acne and androgenic skin effects
- Scalp hair loss in genetically predisposed users: 5α-reductase inhibitors offer limited protection (turinabol has minimal 5α-reduction)
- Exceptionally long detection window: long-term metabolites detectable for months by modern WADA methodology; the 11–14 day "short-term" window users assume is dangerously misleading and has caused dozens of retrospective Olympic medal disqualifications
- No legitimate pharmaceutical supply: all current supply is from unregulated producers with the usual purity/identity/sterility concerns
Key facts
Key facts worth knowing
- Turinabol is structurally a hybrid: it is the 4-chloro derivative of methandienone (Dianabol), combining the 17α-methyl modification (for oral bioavailability), the C1-C2 double bond, and a chlorine atom added at the C4 position. The chlorine modification is what distinguishes turinabol from methandienone.
- The 4-chloro modification prevents aromatization to estrogen; turinabol cannot be converted to estradiol. It also reduces conversion to estrogenic metabolites that occur with methandienone.
- Turinabol is described as having a moderate hepatotoxicity profile: generally milder than oxymetholone, methandienone, or methylated testosterone, but still meaningful due to the 17α-alkylation.
- The compound has an exceptionally long detection window. Modern anti-doping methodology can detect long-term metabolites in urine for up to several months after use. This advancement in detection capability, developed in the 2010s, has retroactively caught athletes who used turinabol believing it had cleared their systems based on older detection assumptions. This led to numerous retrospective Olympic medal disqualifications, particularly from the 2008 and 2012 Games.
- The East German doping program produced significant documented harm to athletes, including: virilization in female athletes (often irreversible), hepatic injury, cardiovascular effects, reproductive complications, and psychological consequences. Many former East German athletes have received financial compensation through the German government's Doping Victims Help Act (Dopingopfer-Hilfegesetz) passed in 2002. Franke WW & Berendonk B, Clinical Chemistry 1997
- The compound has no current legitimate pharmaceutical or medical use in any jurisdiction.
Legal status
Legal status
Schedule III controlled substance in the United States (DEA). No FDA approval; no current human therapeutic use anywhere. WADA-prohibited at all times in competitive sport.